RealFeedApp Immorta Bio plans first human evaluation before year-end
Immorta Bio completed preclinical trials for SenoMune-0257, an AI-designed peptide that activates T cells to clear senescent cells. The molecule consists of only nine amino acids and targets chronic inflammation and tissue deterioration.
- Field
- ageing and longevity
- What they did
- Immorta Bio developed a short peptide that prompts immune cells to eliminate senescent cells, nicknamed 'zombie cells', and has completed its planned preclinical studies.
- Why it matters
- Removing these cells in experiments has shown benefits for treating cardiovascular disease, cancer, and other conditions linked to chronic inflammation.
#senolytics#senescent cells#ai design#peptide therapy#immorta bio
